Tumor necrosis factor-α and transforming growth factor-β reflect severity of liver damage in primary biliary cirrhosis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 17, Issue 2, 2002, Pages 196-202

  Neuman, Manuela ^a,b   Angulo, Paul ^c   Malkiewicz, Izabella ^a,b   Jorgensen, Roberta ^c   Shear, Neil ^a,b   Dickson, E Rolland ^c   Haber, Julia ^a,b   Katz, Gady ^a,b   Lindor, Keith ^c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MAYO CLINIC   (United States)

Author keywords

Bile acids; Cytokines; Fibrosis; Hepatocytotoxicity; Immunomodulation; Primary biliary cirrhosis; Transforming growth factor ; Tumor necrosis factor ; Ursodeoxycholic acid

Indexed keywords

PLACEBO; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT CODING; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0036226760     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2002.02672.x     Document Type: Article

References (36)

1. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis
2. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
3. The Canadian multicenter double-blind randomised controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
4. A randomised double-blind placebo controlled trial of ursodeoxycholate in primary biliary cirrhosis
5. Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study
6. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: Results of a double-blind controlled multicentric trial
7. Combined analysis of randomised controlled trials of ursodeoxycholic acid in primary biliary cirrhosis
8. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis
9. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis
10. Randomised controlled trials of ursodeoxycholic acid therapy for primary biliary cirrhosis: A meta-analysis
11. Ursodeoxycholic acid for primary biliary cirrhosis: Lessons from the past-issues for the future
12. Hepatocytes and immune system: Acute phase reactions as a contribution to early defense mechanism
13. Effects of cytokines on the liver
14. Cytokines and inflamed liver
15. Cytokines in the liver
16. Cytokines: Overview
17. Tumor necrosis factor, cholestatic jaundice and chronic liver disease
18. Endogenous tumour necrosis factor in cancer patients
19. Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C
20. Predictors of sustained response to interferon therapy in chronic hepatitis C
21. Relationship between serum cytokine level, degree of liver damage and ursodeoxycholate in patients with primary biliary cirrhosis
22. Prognosis in primary biliary cirrhosis: Model for decision making
23. Staging of chronic nonspurative destructive cholangitis (syndrome of primary biliary cirrhosis)
24. Role of cytokines in ethanol induced hepatocytotoxicity in Hep G2 cells
25. Laboratory measurement of human cytokines
26. Ductular expression of autoantigens in primary biliary cirrhosis
27. Immunological control in primary biliary cirrhosis: The cytokine story
28. Lymphocytes response and cytokines
29. Analysis of rearranged T cell receptor (TCR) Vβ transcripts in livers of primary biliary cirrhosis: Preferential Vβ usage suggests antigen-driven selection
30. Cytokine mRNA expression in the liver of patients with primary biliary cirrhosis and chronic hepatitis B
31. Analysis of serum cytokine levels in PBC patients and healthy adults
32. Cytokine patterns and cytotoxic mediators in primary biliary cirrhosis
33. Bile duct epithelia as target cells in primary biliary cirrhosis and primary sclerosing cholangitis
34. Serum IL-2 and TNF-α in PBC: Decrease by colchicine and relationship to HLA-DR4
35. Predictive factors in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: Role of serum markers of connective tissue
36. Multivesicular stellate cells in primary biliary cirrhosis